Clinical StudyEmergence of Mycoplasma genitalium strains showing mutations associated with macrolide and fluoroquinolone resistance in the region Dresden, Germany
Section snippets
Acknowledgement
The authors thank S. Müksch, C. Seiler and C. Thomas for technical assistance.
References (27)
- et al.
Sitafloxacin: antimicrobial activity against ciprofloxacin-selected laboratory mutants of Mycoplasma genitalium and inhibitory activity against its DNA gyrase and topoisomerase IV
J Infect Chemother
(2015) - et al.
Isolation of Mycoplasma genitalium from patients with urogenital infections: first report from the Latin-American region
New Microbes New Infect
(2013) - et al.
Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance
Int J Antimicrob Agents
(2010) - et al.
A newly discovered mycoplasma in the human urogenital tract
Lancet
(1981) - et al.
Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens
Clin Infect Dis
(2015) - et al.
Method comparison for molecular typing of French and Tunisian Mycoplasma genitalium-positive specimens
J Med Microbiol
(2012) - et al.
Mycoplasma genitalium infection: current treatment options, therapeutic failure, and resistance-associated mutations
Infect Drug Resist
(2015) - et al.
Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance
Int J STD AIDS
(2013) - et al.
Mycoplasma genitalium: a review
Int J STD AIDS
(2014) - et al.
Multidrug-resistant Mycoplasma genitalium is increasing
Clin Infect Dis
(2016)
Drug resistance-associated mutations in Mycoplasma genitalium in female sex workers, Japan
Emerg Infect Dis
Mycoplasma genitalium infection is associated with microscopic signs of cervical inflammation in liquid cytology specimens
J Clin Microbiol
Mycoplasma genitalium presence, resistance and epidemiology in Greenland
Int J Circumpolar Health
Cited by (41)
Molecular basis of antimicrobial resistance in Mycoplasma genitalium
2020, International Journal of Antimicrobial AgentsMycoplasma genitalium macrolide resistance update: Rate among a 2016–2017 cohort of patients in Barcelona, Spain
2020, Enfermedades Infecciosas y Microbiologia ClinicaCitation Excerpt :Moxifloxacin (MXF) is currently recommended as second-line antibiotic.5 Nevertheless, MXF resistance is appearing in many countries,19–22 including Spain (<10%),8,23 associated with point mutations in the quinolone resistance determining region (QRDR) of the parC and gyrA genes. In 2016, as a response to the increasing macrolide resistance in M. genitalium and the lack of therapeutic alternatives, international treatment guidelines have recommended AZM to be replaced as the initial treatment for NGU with doxycycline (DOX) 100 mg twice daily for one week.24
Mycoplasma genitalium prevalence in Welsh sexual health patients: Low antimicrobial resistance markers and no association of symptoms to bacterial load
2020, Microbial PathogenesisCitation Excerpt :Similar to recent reports from Australia and Canada [7,21], we found MG-MRM rates higher in males (30.8%) compared to females (11.8%). However, our overall MRM rate (20%) was much lower than the 82.4% MRM recently reported for England [22], as well as those reported recently for China (88.9% [15]), Queensland Australia (75.9% [17]), New Zealand (77.4% [23]), Alberta Canada (66.2% [7]), and Germany (52.6% [24]). Our 3.3% overall fluoroquinolone resistance mutation (FRM) rate was similar 4.9% to England (4.9% [22]).
Prevalence of macrolide- and fluoroquinolone-resistant Mycoplasma genitalium strains in clinical specimens from men who have sex with men of two sexually transmitted infection practices in Berlin, Germany
2019, Journal of Global Antimicrobial ResistanceCitation Excerpt :Descriptions of multidrug-resistant strains (combined macrolide and quinolone resistance) and the limited repertoire of well-tested, effective and approved therapy alternatives increase concern regarding untreatable M. genitalium infections [1]. Apart from one report that characterised a small number of samples [7], there is no information about the resistance pattern of M. genitalium strains circulating in Germany. This is especially the case for risk populations.
Urethritis—spectrum of pathogens, diagnostics and treatment
2023, Dermatologie